WO2022121813A1 - Inhibiteur de sos1, composition pharmaceutique le comprenant et son utilisation - Google Patents

Inhibiteur de sos1, composition pharmaceutique le comprenant et son utilisation Download PDF

Info

Publication number
WO2022121813A1
WO2022121813A1 PCT/CN2021/135591 CN2021135591W WO2022121813A1 WO 2022121813 A1 WO2022121813 A1 WO 2022121813A1 CN 2021135591 W CN2021135591 W CN 2021135591W WO 2022121813 A1 WO2022121813 A1 WO 2022121813A1
Authority
WO
WIPO (PCT)
Prior art keywords
ring
compound
alkyl
membered
cancer
Prior art date
Application number
PCT/CN2021/135591
Other languages
English (en)
Chinese (zh)
Inventor
赵焰平
王红军
张道广
王晓倩
侯翠柳
冯泽旺
Original Assignee
北京泰德制药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京泰德制药股份有限公司 filed Critical 北京泰德制药股份有限公司
Priority to CN202180081795.1A priority Critical patent/CN116568681A/zh
Publication of WO2022121813A1 publication Critical patent/WO2022121813A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Abstract

L'invention concerne un inhibiteur de SOS1 représenté par la formule (I) ou la formule (I'), une composition pharmaceutique le comprenant, et une utilisation de celui-ci pour la prévention ou le traitement de maladies.
PCT/CN2021/135591 2020-12-07 2021-12-06 Inhibiteur de sos1, composition pharmaceutique le comprenant et son utilisation WO2022121813A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202180081795.1A CN116568681A (zh) 2020-12-07 2021-12-06 Sos1抑制剂、包含其的药物组合物及其用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/134233 2020-12-07
CN2020134233 2020-12-07

Publications (1)

Publication Number Publication Date
WO2022121813A1 true WO2022121813A1 (fr) 2022-06-16

Family

ID=81973062

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/135591 WO2022121813A1 (fr) 2020-12-07 2021-12-06 Inhibiteur de sos1, composition pharmaceutique le comprenant et son utilisation

Country Status (3)

Country Link
CN (1) CN116568681A (fr)
TW (1) TW202229291A (fr)
WO (1) WO2022121813A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115141188A (zh) * 2022-07-12 2022-10-04 江南大学 一种取代喹唑啉类化合物、药物组合物及其用途
WO2023134374A1 (fr) * 2022-01-12 2023-07-20 如东凌达生物医药科技有限公司 Composé pyrimido-hétérocyclique, procédé de préparation et utilisation
WO2023165438A1 (fr) * 2022-03-03 2023-09-07 浙江海正药业股份有限公司 Dérivé tricyclique, son procédé de préparation et son utilisation
WO2024074827A1 (fr) 2022-10-05 2024-04-11 Sevenless Therapeutics Limited Nouveaux traitements de la douleur

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1139430A (zh) * 1994-01-25 1997-01-01 沃尼尔朗伯公司 能够抑制表皮生长因子受体族之酪氨酸激酶的三环化合物
WO2008020711A1 (fr) * 2006-08-16 2008-02-21 Chong Kun Dang Pharmaceutical Corp. Dérivé de quinazoline comme inhibiteur de phosphodiesterase et procédé d'élaboration correspondant
WO2018172250A1 (fr) * 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-méthyl-quinazolines
CN110167928A (zh) * 2016-12-22 2019-08-23 勃林格殷格翰国际有限公司 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物
WO2021130731A1 (fr) * 2019-12-27 2021-07-01 Lupin Limited Composés tricycliques substitués
WO2021203768A1 (fr) * 2020-04-08 2021-10-14 江苏恒瑞医药股份有限公司 Dérivé pyrimido dicyclo, son procédé de préparation et son utilisation en médecine
WO2021249475A1 (fr) * 2020-06-10 2021-12-16 江苏恒瑞医药股份有限公司 Dérivé de quinazoline condensé, son procédé de préparation et son application en médecine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1139430A (zh) * 1994-01-25 1997-01-01 沃尼尔朗伯公司 能够抑制表皮生长因子受体族之酪氨酸激酶的三环化合物
WO2008020711A1 (fr) * 2006-08-16 2008-02-21 Chong Kun Dang Pharmaceutical Corp. Dérivé de quinazoline comme inhibiteur de phosphodiesterase et procédé d'élaboration correspondant
CN110167928A (zh) * 2016-12-22 2019-08-23 勃林格殷格翰国际有限公司 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物
WO2018172250A1 (fr) * 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-méthyl-quinazolines
WO2021130731A1 (fr) * 2019-12-27 2021-07-01 Lupin Limited Composés tricycliques substitués
WO2021203768A1 (fr) * 2020-04-08 2021-10-14 江苏恒瑞医药股份有限公司 Dérivé pyrimido dicyclo, son procédé de préparation et son utilisation en médecine
WO2021249475A1 (fr) * 2020-06-10 2021-12-16 江苏恒瑞医药股份有限公司 Dérivé de quinazoline condensé, son procédé de préparation et son application en médecine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HILLIG ROMAN C., SAUTIER BRICE, SCHROEDER JENS, MOOSMAYER DIETER, HILPMANN ANDRé, STEGMANN CHRISTIAN M., WERBECK NICOLAS D., : "Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 116, no. 7, 12 February 2019 (2019-02-12), pages 2551 - 2560, XP055841142, ISSN: 0027-8424, DOI: 10.1073/pnas.1812963116 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023134374A1 (fr) * 2022-01-12 2023-07-20 如东凌达生物医药科技有限公司 Composé pyrimido-hétérocyclique, procédé de préparation et utilisation
WO2023165438A1 (fr) * 2022-03-03 2023-09-07 浙江海正药业股份有限公司 Dérivé tricyclique, son procédé de préparation et son utilisation
CN115141188A (zh) * 2022-07-12 2022-10-04 江南大学 一种取代喹唑啉类化合物、药物组合物及其用途
WO2024074827A1 (fr) 2022-10-05 2024-04-11 Sevenless Therapeutics Limited Nouveaux traitements de la douleur

Also Published As

Publication number Publication date
TW202229291A (zh) 2022-08-01
CN116568681A (zh) 2023-08-08

Similar Documents

Publication Publication Date Title
CN109071498B (zh) 激酶抑制剂及其制备方法和用途
JP2023126907A (ja) Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
JP7039802B2 (ja) Ｒｈｏ－関連プロテインキナーゼ阻害剤、ｒｈｏ－関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
WO2022121813A1 (fr) Inhibiteur de sos1, composition pharmaceutique le comprenant et son utilisation
TWI617559B (zh) ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
WO2019134539A1 (fr) Composé de dihydropyrazolone et de pyrimidine, son procédé de préparation et son utilisation
JP2020525525A (ja) Ｒｈｏ−関連プロテインキナーゼ阻害剤、ｒｈｏ−関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
WO2019101086A1 (fr) Inhibiteur de ssao/vap-1 halo-allylamine et son utilisation
WO2022028506A1 (fr) Inhibiteur de sos1, composition pharmaceutique le contenant et son utilisation
WO2021143701A1 (fr) Composé hétérocyclique de pyrimidine-4(3h)-cétone, son procédé de préparation et son utilisation en médecine et en pharmacologie
WO2022193871A1 (fr) Préparation et utilisation d'un inhibiteur de la protéine mutante krasg12d
WO2021041976A1 (fr) Composés indolinyle inhibiteurs de perk
WO2023011513A1 (fr) Inhibiteur de shp2, composition pharmaceutique le comprenant et son application
WO2021041970A1 (fr) Composés d'imidazolopyrazine inhibiteurs de perk
WO2022237676A1 (fr) Préparation et application d'un inhibiteur de la phosphatase shp2
WO2022089389A1 (fr) Composé hétérocyclique, procédé de préparation s'y rapportant, composition pharmaceutique associée et application associée
IL293107A (en) Adenosine receptor antagonist compounds
WO2021078227A1 (fr) Dérivé d'hétéroaryle fusionné, son procédé de préparation et son utilisation en médecine
WO2020094111A1 (fr) Inhibiteur de protéine kinase associée à rho, composition pharmaceutique le comprenant et son utilisation
JP7387208B2 (ja) ビフェニル基フッ素置換二重結合誘導体、その製造方法と薬学的な応用
JP7381170B2 (ja) 受容体阻害剤、同阻害剤を含む医薬組成物及びその使用
WO2023083373A1 (fr) Composé utilisé comme inhibiteur de src
WO2022257875A1 (fr) Composé pyrimidine, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
WO2022171126A1 (fr) Composé cyclique fusionné utilisé comme inhibiteur de wee-1
WO2023016296A1 (fr) Composé hétérocyclique, son procédé de préparation et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21902520

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202180081795.1

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21902520

Country of ref document: EP

Kind code of ref document: A1